Bartlett DL - Search Results

1

Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.

Amblard I, Mercier F, Bartlett DL, Ahrendt SA, Lee KW, Zeh HJ, Levine EA, Baratti D, Deraco M, Piso P, Morris DL, Rau B, Tentes AAK, Tuech JJ, Quenet F, Akaishi E, Pocard M, Yonemura Y, Lorimier G, Delroeux D, Villeneuve L, Glehen O, Passot G; PSOGI and BIG RENAPE working groups. Amblard I, et al. Among authors: bartlett dl. Eur J Surg Oncol. 2018 Sep;44(9):1378-1383. doi: 10.1016/j.ejso.2018.04.023. Epub 2018 Jun 19. Eur J Surg Oncol. 2018. PMID: 30131104

2

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers.

Zeh HJ, Bartlett DL. Zeh HJ, et al. Among authors: bartlett dl. Cancer Gene Ther. 2002 Dec;9(12):1001-12. doi: 10.1038/sj.cgt.7700549. Cancer Gene Ther. 2002. PMID: 12522439 Review.

3

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. Guo ZS, et al. Among authors: bartlett dl. Cancer Res. 2005 Nov 1;65(21):9991-8. doi: 10.1158/0008-5472.CAN-05-1630. Cancer Res. 2005. PMID: 16267024

4

Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix.

Maheshwari V, Tsung A, Lin Y, Zeh HJ 3rd, Finkelstein SD, Bartlett DL. Maheshwari V, et al. Among authors: bartlett dl. Ann Surg Oncol. 2006 Dec;13(12):1610-6. doi: 10.1245/s10434-006-9081-1. Epub 2006 Sep 29. Ann Surg Oncol. 2006. PMID: 17009159

5

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.

Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G; Society of Surgical Oncology Annual Meeting. Esquivel J, et al. Ann Surg Oncol. 2007 Jan;14(1):128-33. doi: 10.1245/s10434-006-9185-7. Epub 2006 Oct 28. Ann Surg Oncol. 2007. PMID: 17072675 No abstract available.

6

High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.

Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ 3rd. Popovic PJ, et al. Among authors: bartlett dl. J Immunol. 2006 Dec 15;177(12):8701-7. doi: 10.4049/jimmunol.177.12.8701. J Immunol. 2006. PMID: 17142771

7

Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE. Zeh HJ, et al. Cancer Biomark. 2005;1(6):259-69. doi: 10.3233/cbm-2005-1601. Cancer Biomark. 2005. PMID: 17192050

8

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.

Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL. Yang S, et al. Among authors: bartlett dl. Gene Ther. 2007 Apr;14(8):638-47. doi: 10.1038/sj.gt.3302914. Epub 2007 Feb 1. Gene Ther. 2007. PMID: 17268533

9

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, Watkins S, Winikoff S, Brown CK, Bartlett DL, Zeh HJ 3rd. Dong Xda E, et al. Among authors: bartlett dl. J Immunother. 2007 Sep;30(6):596-606. doi: 10.1097/CJI.0b013e31804efc76. J Immunother. 2007. PMID: 17667523

10

Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.

Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Gusani NJ, et al. Among authors: bartlett dl. Ann Surg Oncol. 2008 Mar;15(3):754-63. doi: 10.1245/s10434-007-9701-4. Epub 2007 Dec 12. Ann Surg Oncol. 2008. PMID: 18080166 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters